Description

Fludamax 50 mg contains Fludarabine Phosphate, a purine analog antimetabolite widely used in hematologic oncology. It is administered intravenously in hospital settings as part of chemotherapy regimens for specific blood cancers.

🔬 Mechanism of Action

Fludarabine is converted inside the body to its active metabolite (2-fluoro-ara-ATP), which interferes with DNA polymerase, ribonucleotide reductase, and DNA primase. As a result, it disrupts DNA synthesis and repair, leading to inhibition of cancer cell growth and eventual cell death.

💊 Indications

Fludamax 50 mg is indicated for:

• Chronic Lymphocytic Leukemia (CLL) in patients who have not responded to other therapies
• Low-grade Non-Hodgkin Lymphoma (NHL)
• Other hematologic malignancies as prescribed by an oncologist

📌 Key Features of Fludamax 50 mg

• Strength: 50 mg
• Dosage Form: Injection for intravenous infusion
• Therapeutic Class: Purine Analog / Antimetabolite Chemotherapy
• Administration: Given via IV infusion under medical supervision
• Monitoring: Regular complete blood count (CBC), kidney function, and infection monitoring required

⚕️ Benefits of Fludarabine

• Effective therapy for certain blood cancers
• Helps reduce malignant lymphocyte proliferation
• Often used in combination chemotherapy regimens
• Supports improved disease control in relapsed cases

⚠️ Precautions

• Severe bone marrow suppression may occur
• Increased risk of infections due to immunosuppression
• Potential neurotoxicity at high doses
• Monitoring of blood counts and renal function required
• Use strictly under oncologist supervision

Fludamax 50 mg (Fludarabine Phosphate Injection) is an important chemotherapy agent in hematologic oncology, helping control disease progression in chronic lymphocytic leukemia and related blood cancers when administered under specialized medical care.